Invention Grant
- Patent Title: Combination of human anti-FGFR4 antibody and Sorafenib
-
Application No.: US16076776Application Date: 2017-02-09
-
Publication No.: US10995143B2Publication Date: 2021-05-04
- Inventor: Reimar Abraham , Keisuke Fukuchi
- Applicant: Daiichi Sankyo Europe GmbH , Daiichi Sankyo Company, Limited
- Applicant Address: DE Munich; JP Tokyo
- Assignee: Daiichi Sankyo Europe GmbH,Daiichi Sankyo Company, Limited
- Current Assignee: Daiichi Sankyo Europe GmbH,Daiichi Sankyo Company, Limited
- Current Assignee Address: DE Munich; JP Tokyo
- Agency: Withers & Key, LLC
- Priority: EP16155056 20160210
- International Application: PCT/EP2017/052893 WO 20170209
- International Announcement: WO2017/137503 WO 20170817
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61K31/44 ; A61P35/00 ; A61K31/4412 ; A61K38/20 ; A61K45/06 ; C07K14/54 ; A61K39/00
Abstract:
The present invention relates to the medical use of antibodies against the FGF receptor 4 (FGFR4) combined with Sorafenib, in particular for the prevention or treatment of hyperproliferative diseases associated with FGFR expression, overexpression or hyperactivity.
Public/Granted literature
- US20190048088A1 COMBINATION OF HUMAN ANTI-FGFR4 ANTIBODY AND SORAFENIB Public/Granted day:2019-02-14
Information query
